Press releases

NORTH CHICAGO, Ill., July 28, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2017.

NORTH CHICAGO, Ill., July 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

NORTH CHICAGO, Ill., July 10, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2017 financial results on Friday, July 28, 2017, before the market opens.

NORTH CHICAGO, Ill., June 26, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and its key partners celebrate the launch of the fourth annual "Week of Possibilities," with more than 6,000 employees expected to volunteer  26,000+ hours in the communities where they live and work. AbbVie volunteers will join forces with nonprofit partners like Heart of America Foundation and Points of Light, engaging in hands-on projects that largely focus on improving educational opportunities for children in underserved communities.

NORTH CHICAGO, Ill., June 23, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending marketing authorization of MAVIRET™ (glecaprevir/pibrentasvir), an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection. If approved, MAVIRET will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes (GT1-6), who comprise the majority of people living with HCV.¹ The European Commission will now review the CHMP opinion and a final decision is expected in Q3 2017.

- First oral presentation of full Phase 2 trial results with overall response rate (ORR), inclusive of complete and partial remission rates(1)

NORTH CHICAGO, Ill., June 22, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. 

- New data of rheumatoid arthritis patients who participated in a HUMIRA (adalimumab) patient support program in select countries showed an association between the use of a patient support program and improvements in functional outcomes

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., June 13, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for the development of oral immunoproteasome inhibitors.  The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. 

- Results from pivotal VENCLYXTO ™ (venetoclax) trial in relapsed/refractory chronic lymphocytic leukemia (CLL) patients with 17p deletion to be presented